Erin F. Gillespie

Erin F. Gillespie

Auto-generated profile, based on publicly available information

Erin F. Gillespie

Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JWJoanne Weidhaas
Joanne Weidhaas
IBImran Babar
Imran Babar
SNSunitha M. Nallur
Sunitha M. Nallur
PTPhong Trang
Phong Trang
SRSarah Roush
Sarah Roush
FSFrank J. Slack
Frank J. Slack
Tumor cells use preexisting prosurvival signaling pathways to evade the damaging and cytotoxic effects of anticancer agents. Radiation therapy is a primary form of cytotoxic anticancer treatment, but agents that successfully modify the radiation response in vivo are lacking. MicroRNAs (miRNA) are global gene regulators that play critical roles in oncogenesis and have been found to regulate prosurvival pathways. However, there is little understanding of how cellular miRNA expression affects the response of a cancer to cytotoxic therapy and ultimately outcome. The let-7 family of miRNAs regulates expression of oncogenes, such as RAS, and is specifically down-regulated in many cancer subtypes. In fact, low levels of let-7 predict a poor outcome in lung cancer. Here, we report that the let-7 family of miRNAs is overrepresented in a class of miRNAs exhibiting altered expression in response to radiation. More strikingly, we also can create a radiosensitive state when the select let-7 family of miRNAs is overexpressed in vitro in lung cancer cells and in vivo in a Caenorhabditis elegans model of radiation-induced cell death, whereas decreasing their levels causes radioresistance. In C. elegans, we show that this is partly through control of the proto-oncogene homologue let-60/RAS and genes in the DNA damage response pathway. These findings are the first direct evidence that miRNAs can suppress resistance to anticancer cytotoxic therapy, a common feature of cancer cells, and suggest that miRNAs may be a viable tool to augment current cancer therapies. [Cancer Res 2007;67(23):11111–6]

11 May 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MSMichael V. Sherer
Michael V. Sherer
DLDiana Lin
Diana Lin
SESharif Elguindi
Sharif Elguindi
SDSimon Duke
Simon Duke
LTLi-Tee Tan
Li-Tee Tan
EGErin F. Gillespie
Erin F. Gillespie

4 May 2009 in Oncogene
Verified
Journal Article
Open access
PDF file
MKM Kato
M Kato
TPT Paranjape
T Paranjape
RUR Ullrich
R Ullrich
SNS Nallur
S Nallur
EGE Gillespie
E Gillespie
FSFrank J. Slack
Frank J. Slack
MicroRNAs (miRNAs) are important regulators of cell fate determination and homeostasis. Expression of these small RNA genes is tightly regulated during development and in normal tissues, but they are often misregulated in cancer. MiRNA expression is also affected by DNA damaging agents, such as radiation. In particular, mammalian miR-34 is upregulated by p53 in response to radiation, but little is known about the role of this miRNA in vivo. Here we show that Caenorhabditis elegans with loss-of-function mutations in the mir-34 gene have an abnormal cellular survival response to radiation; these animals are highly radiosensitive in the soma and radioresistant in the germline. These findings show a role for mir-34 in both apoptotic and non-apoptotic cell death in vivo, much like that of cep-1, the C. elegans p53 homolog. These results have been additionally validated in vitro in breast cancer cells, wherein exogenous addition of miR-34 alters cell survival post-radiation. These observations confirm that mir-34 is required for a normal cellular response to DNA damage in vivo resulting in altered cellular survival post-irradiation, and point to a potential therapeutic use for anti-miR-34 as a radiosensitizing agent in p53-mutant breast cancer.

1 June 2019 in Patient Related Outcome Measures
Verified
Journal Article
Open access
PDF file
ECEric M Chang
Eric M Chang
EGErin F Gillespie
Erin F Gillespie
NSNarek Shaverdian
Narek Shaverdian
The use of patient-reported outcome (PRO) measures in research and clinical care has expanded dramatically, reflective of an increasing recognition of patient-centeredness as an important aspect of high-quality health care. Given this rapid expansion, ensuring that data collected using PRO measures is of high quality is crucial for their continued successful application. Because of the subjective nature of the outcomes assessed, there are many factors that may influence patients’ responses and thus challenge the overall quality of the data. In this review, we discuss the multiple factors that may affect patients’ responses on PRO measures. These factors may arise during instrument development and administration or secondary to patient-level response behaviors. We further examine the relevant literature to delineate how these factors may impact data quality and review methods for accounting for these factors. Consideration of such factors is critical to ensuring data collected truthfully reflects patients’ evaluations and provides accurate conclusions.

1 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EGErin F. Gillespie
Erin F. Gillespie
JYJoanna C. Yang
Joanna C. Yang
NMNoah J. Mathis
Noah J. Mathis
CMCatherine B. Marine
Catherine B. Marine
CWCharlie White
Charlie White
JYJonathan T. Yang
Jonathan T. Yang
In a multicenter RCT (n = 78), radiation to high-risk asymptomatic bone metastases ⬇ skeletal-related events and prolonged OS.

3 March 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ECElaine Cha
Elaine Cha
SESharif Elguindi
Sharif Elguindi
IOIfeanyirochukwu Onochie
Ifeanyirochukwu Onochie
DGDaniel Gorovets
Daniel Gorovets
JDJoseph O. Deasy
Joseph O. Deasy
EGErin F. Gillespie
Erin F. Gillespie